TRAC team grows again

Cornwall-based regulatory affairs specialist appoints three new members of staff

Natalie Grogan, Debbie Finlay and Mike May have joined Cornwall's TRAC, which works with pharmaceutical companies to ensure that they are meeting their regulatory responsibilities.

Grogan takes the role of marketing manager, having relocated from Manchester where she has spent the last seven years in the marketing department of fashion and footwear home retailer JD Williams & Co.

Finlay and May boost TRAC’s Regulatory Affairs team, where they will be working on a range of projects for clients across Europe.

After spending 12 years living and working in Boston, US, Finlay returned to Cornwall in 2005 and graduated with a degree in Biological Science in 2009.

May graduated from Indiana State University in 2007 before relocating to study at the University of Plymouth where he gained a BSc in Human Biosciences.

‘We are delighted to have secured the services of Natalie, Debbie and Mike in the latest part of our development programme. They bring not only experience but also enthusiasm and a real desire to be part of the TRAC success story,’ said TRAC director Sarah Trethowan.

You may also like

Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Manufacturing

IMed Consultancy helps Toby Orthopaedics navigate UK regulations

Regulatory consultancy ensures compliance and confidence for Miami-based company
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Design & Build

Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies

Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
Subscribe now